Nuvalent Inc.
Nuvalent Submits NDA for Neladalkib and Advances Zidesamtinib Review
Summary
Nuvalent, Inc. announced the submission of its NDA for neladalkib, an ALK-selective inhibitor for TKI pre-treated advanced ALK-positive NSCLC, and provided an update on the ongoing FDA review of its NDA for zidesamtinib, a ROS1-selective inhibitor for TKI pre-treated advanced ROS1-positive NSCLC, with a PDUFA target action date of September 18, 2026. The company also highlighted recent leadership promotions and reported its first quarter 2026 financial results, including a cash position of $1.3 billion as of March 31, 2026.
Profitelligence Alerts
Get alerts for NUVL
Be first to know when Nuvalent Inc. files with the SEC.
Filing Categories
Advertisement
About Nuvalent Inc.
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for patients with cancer-related resistance mutations and treatment-related adverse effects. By leveraging their expertise in medicinal chemistry and deep understanding of tumor biology, Nuvalent aims to address significant gaps in current cancer therapies, particularly where existing treatments fall short due to resistance mechanisms. The company operates in a highly specialized sector that covers oncology research and development, presenting potential game-changing approaches within the broader pharmaceutical industry. Through its commitment to research and innovation, Nuvalent collaborates with leading research institutions to push the boundaries of what is achievable in cancer treatment. Situated within an ever-evolving market, the company plays a critical role in advancing new oncological solutions that may ultimately improve the quality of life for patients globally. Founded with the mission to transform patient care, Nuvalent's asset offerings are a testament to the progressive strides being made in next-generation cancer therapeutics.
Official SEC Documents
Advertisement